Patents Assigned to Fulcrum Therapeutics, Inc.
  • Compositions and methods for modulating FMR1 expression
    Patent number: 11819554
    Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITY OF MASSACHUSETTS, FULCRUM THERAPEUTICS, INC.
    Inventors: Michael R. Green, Minggang Fang, Walter Kowtoniuk
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 11590111
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: February 28, 2023
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • Use of p38 inhibitors to reduce expression of DUX4
    Patent number: 11479770
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 11291659
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 5, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 10973805
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10537560
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 21, 2020
    Assignee: Fulcrum Therapeutics. Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10342786
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: July 9, 2019
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • COMPOSITIONS AND METHODS FOR MODULATING FMR1 EXPRESSION
    Publication number: 20180256749
    Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Applicants: University of Massachusetts, Fulcrum Therapeutics, Inc.
    Inventors: Michael R. Green, Minggang Fang, Walter Kowtoniuk